The Motley Fool

Here are my best stocks to buy in July

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Compass pointing towards 'best price'
Image source: Getty Images.

Historically the stock market doesn’t tend to move much in July and August as many people are on holiday. However, given that the world is still in the middle of a pandemic, I think it’s fair to say that history might not repeat itself in 2021. This means there could be several lucrative investments to make this month. So, let’s look at two companies that might be the best stocks to buy in July for my portfolio.

Is GlaxoSmithKline becoming a growth stock?

For many years, GlaxoSmithKline (LSE:GSK) hasn’t been a particularly stellar performer. Looking over the past decade, the GSK share price has increased by a grand total of 7%. Total shareholder returns have obviously been much higher thanks to its sizable dividends. But under the new leadership of CEO Emma Walmsley, the company is now undergoing a massive transformation in which dividends are expected to suffer.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

The plan is to spin out its consumer healthcare division into its own entity in 2022. The remaining business will be focused entirely on the development of vaccines and new medicines. And given that such products can be highly profitable, the management team expects to achieve a 5% compound annual growth rate.

If successful, total sales are expected to reach £33bn by 2031. That’s a 37% increase compared to what its pharmaceutical and vaccine divisions generated in 2020. Today the company has a market capitalisation of around £72bn. So, taking this forecast, the stock looks exceptionally cheap in my eyes. However, there are some major risks involved in becoming a pureplay drug developer. The main one being a clinical trial failure. In the end, all it takes is one phase III trial to fail to make a multi-billion-pound investment go down the drain. But given Glaxo’s track record and experience, I think this risk may be worth taking. That’s why it’s on the list of best stocks to buy this July for my portfolio.

The best stocks to buy have their risks

A new Saga?

Saga (LSE:SAGA) is another business currently undergoing transformation. After years of mismanagement, the company’s original owner decided to make a comeback and turn the ship around. As the board’s new chairman, Sir Roger De Haan revamped the management team and has swiftly begun restructuring the entire business.

While unpleasant for many now-ex-employees, this process seems to have saved the company from the brink of bankruptcy. Total losses have been cut by 80%, its cruise line travel division has seen 20% growth in bookings, and Saga’s long-time underperforming insurance business finally saw some improvement. It’s quite an impressive turnaround, in my opinion. And with the rapid progress of the vaccine rollout easing travel restrictions, this growth might continue throughout the rest of 2021. That’s why it’s on my portfolio’s best stocks to buy list this month. But it’s hardly going to be smooth sailing from here.

As promising as its progress is, there remain some significant issues with the balance sheet. Currently, the business has around £823m of debt to contend with and not much cash available. It did recently complete a tender offer that raised £100m of capital. But this was far less than the anticipated £250m. Needless to say, if Saga is unable to bring its debts under control over the long term, it could be the end of its turnaround story.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.